480 related articles for article (PubMed ID: 34555298)
21. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.
Zhang N; Li H; Wang D; Wang Z; Zhu JS; Chen K; Jiang H; Shao JB; Cai C
Clin Epigenetics; 2024 May; 16(1):63. PubMed ID: 38725010
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
[No Abstract] [Full Text] [Related]
23. Chidamide and Decitabine in Combination with a HAG Priming Regimen for Acute Myeloid Leukemia with TP53 Mutation.
Zhang B; Pei Z; Wang H; Wu H; Wang J; Bai J; Song Q
Acta Med Okayama; 2022 Feb; 76(1):63-70. PubMed ID: 35237000
[TBL] [Abstract][Full Text] [Related]
24. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis.
Cao Y; Liu Y; Shang L; Wei W; Shen Y; Gu Q; Xie X; Dong W; Lin Y; Yue Y; Wang F; Gu W
Biomed Pharmacother; 2020 May; 125():109878. PubMed ID: 32006898
[TBL] [Abstract][Full Text] [Related]
25. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Duong VH; Ruppert AS; Mims AS; Borate U; Stein EM; Baer MR; Stock W; Kovacsovics T; Blum W; Arellano ML; Schiller GJ; Olin RL; Foran JM; Litzow MR; Lin TL; Patel PA; Foster MC; Redner RL; Al-Mansour Z; Cogle CR; Swords RT; Collins RH; Vergilio JA; Heerema NA; Rosenberg L; Yocum AO; Marcus S; Chen T; Druggan F; Stefanos M; Gana TJ; Shoben AB; Druker BJ; Burd A; Byrd JC; Levine RL; Boyiadzis MM
Cancer; 2023 Aug; 129(15):2308-2320. PubMed ID: 37078412
[TBL] [Abstract][Full Text] [Related]
26. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
Ritchie EK; Feldman EJ; Christos PJ; Rohan SD; Lagassa CB; Ippoliti C; Scandura JM; Carlson K; Roboz GJ
Leuk Lymphoma; 2013 Sep; 54(9):2003-7. PubMed ID: 23270581
[TBL] [Abstract][Full Text] [Related]
27. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
28. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
[TBL] [Abstract][Full Text] [Related]
29. Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.
Wu W; Lin Y; Xiang L; Dong W; Hua X; Ling Y; Li H; Yan F; Xie X; Gu W
Ann Hematol; 2016 Jun; 95(7):1051-7. PubMed ID: 27116384
[TBL] [Abstract][Full Text] [Related]
30. [The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].
Ai H; Wei XD; Yin QS; Wang P; Mi RH; Yuan FF; Chen L; Song YP
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):606-609. PubMed ID: 28789495
[TBL] [Abstract][Full Text] [Related]
31. Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.
Gupta N; Miller A; Gandhi S; Ford LA; Vigil CE; Griffiths EA; Thompson JE; Wetzler M; Wang ES
Am J Hematol; 2015 Jul; 90(7):639-46. PubMed ID: 25808347
[TBL] [Abstract][Full Text] [Related]
32. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Daver N; Kantarjian H; Garcia-Manero G; Jabbour E; Borthakur G; Brandt M; Pierce S; Vaughan K; Ning J; Nogueras González GM; Patel K; Jorgensen J; Pemmaraju N; Kadia T; Konopleva M; Andreeff M; DiNardo C; Cortes J; Ward R; Craig A; Ravandi F
Haematologica; 2017 Oct; 102(10):1709-1717. PubMed ID: 28729302
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Kim K; Maiti A; Loghavi S; Pourebrahim R; Kadia TM; Rausch CR; Furudate K; Daver NG; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Tang G; Ravandi F; Kantarjian HM; DiNardo CD; Konopleva MY
Cancer; 2021 Oct; 127(20):3772-3781. PubMed ID: 34255353
[TBL] [Abstract][Full Text] [Related]
34. [Comparative analysis of decitabine combined with DAG regimen and other regimens in treatment of refractory/relapsed acute myeloid leukemia].
Hao J; Wang L; Wang Y; Liu Z; Gu X; Liu J; Li L; Duan Y; Chen Y; Zhao W; Shen Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):481-5. PubMed ID: 24985167
[TBL] [Abstract][Full Text] [Related]
35. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
[TBL] [Abstract][Full Text] [Related]
37. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
[TBL] [Abstract][Full Text] [Related]
38. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Kadia TM; Ravandi F; Borthakur G; Konopleva M; DiNardo CD; Daver N; Pemmaraju N; Kanagal-Shamanna R; Wang X; Huang X; Pierce S; Rausch C; Burger J; Ferrajoli A; Jain N; Popat U; Estrov Z; Verstovsek S; Jabbour E; Garcia-Manero G; Kantarjian H
Am J Hematol; 2021 Aug; 96(8):914-924. PubMed ID: 33901324
[TBL] [Abstract][Full Text] [Related]
39. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
40. [Clinical efficacy of decitabine plus improved CAG chemotherapy and haplo-identical donor peripheral lymphocyte infusion regimen on elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia].
Dou LP; Jing Y; Wang QS; Mei JH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):662-6. PubMed ID: 23815918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
